Newer antipsychotics and upcoming molecules for schizophrenia.

Item

http://www.wikidata.org/entity/Q38094930

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Newer antipsychotics and upcoming molecules for schizophrenia.

@en

type

Item

label

Newer antipsychotics and upcoming molecules for schizophrenia.

@en

prefLabel

Newer antipsychotics and upcoming molecules for schizophrenia.

@en

P1476

Newer antipsychotics and upcoming molecules for schizophrenia.

@en

P2093

Melvin George

http://www.w3.org/2001/XMLSchema#string

Radhika Amrutheshwar

http://www.w3.org/2001/XMLSchema#string

Ravi Philip Rajkumar

http://www.w3.org/2001/XMLSchema#string

Shivanand Kattimani

http://www.w3.org/2001/XMLSchema#string

Steven Aibor Dkhar

http://www.w3.org/2001/XMLSchema#string

P2860

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

Evaluation of the clinical efficacy of asenapine in schizophrenia

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

P2888

s00228-013-1498-4

P304

1497-1509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-013-1498-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018508659

http://www.w3.org/2001/XMLSchema#string

P698

23545936

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia